Wednesday, April 01, 2020 2:41:10 PM
Recent AIM News
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/18/2024 12:45:00 PM
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs • GlobeNewswire Inc. • 04/15/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/11/2024 03:00:00 PM
- AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer • GlobeNewswire Inc. • 04/10/2024 12:21:00 PM
- AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:05:00 PM
- AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 03/26/2024 01:05:00 PM
- AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research • GlobeNewswire Inc. • 03/25/2024 01:05:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 03/22/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 03/20/2024 01:25:00 PM
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity • GlobeNewswire Inc. • 03/15/2024 12:45:00 PM
- AIM ImmunoTech Announces Launch of CEO Corner Platform • GlobeNewswire Inc. • 03/07/2024 01:45:00 PM
- AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 01:45:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 02/21/2024 03:37:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:31:03 PM
- AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 02/14/2024 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 08:47:35 PM
- AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions • GlobeNewswire Inc. • 02/08/2024 01:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:00:16 PM
- AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer • GlobeNewswire Inc. • 01/24/2024 02:10:00 PM
- AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 01/22/2024 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 06:42:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 01:45:12 PM
- AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 01/10/2024 01:45:00 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM